| CAS NO: | 847249-57-4 |
| 包装 | 价格(元) |
| 500µg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| Cas No. | 847249-57-4 |
| Canonical SMILES | CC(C)(C)C1=CC=C(C(NC2=CC=C(C(NO)=O)C=C2)=O)C=C1 |
| 分子式 | C18H20N2O3 |
| 分子量 | 312.4 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml,Ethanol: 1 mg/ml |
| 储存条件 | 4°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | AES-350 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.605, 0.187, and 0.245 µM for HDAC1, -3, and -8, respectively) and class IIb HDACs (IC50s = 0.0244 and 0.899 µM for HDAC6 and HDAC10, respectively).1It is selective for class I and class IIb HDACs over HDAC2, -4, -5, -7, -9, and -11 (IC50s = >1 µM for all). AES-350 is cytotoxic to MV4-11, MOLM-13, and MRC-9 cells (IC50s = 0.576, 6, and 33.2 µM, respectively). It induces apoptosis in MV4-11 cells in a concentration-dependent manner. 1.Shouksmith, A.E., Gawel, J.M., Nawar, N., et al.Class I/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemiaACS Med. Chem. Lett.11(1)56-64(2019) |
m.cnreagent.com